Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shuiping Zhao & Daoquan Peng. (2018) Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study. Current Medical Research and Opinion 34:2, pages 227-235.
Read now
Read now
Zhen Wang & Junbo Ge. (2014) Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin. Clinical Interventions in Aging 9, pages 1-8.
Read now
Read now
Juan-Osvaldo Talavera, Gustavo Martinez, Jose-Luis Cervantes, Javier-Aguila Marin, Ignacio Rodriguez-Briones, Jose-Gerardo Gonzalez, Rodolfo Ocampo, Hector Sanchez-Mijangos, Laura P. Bernal-Rosales & Ana Polanco. (2013) A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients. Current Medical Research and Opinion 29:4, pages 379-386.
Read now
Read now
Toivo Laks, Ester Keba, Mariann Leiner, Eero Merilind, Mall Petersen, Sirje Reinmets, Sille Väli, Terje Sööt & Karin Otter. (2008) Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study. Vascular Health and Risk Management 4:6, pages 1407-1416.
Read now
Read now
Handrean Soran & Paul Durrington. (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy 9:12, pages 2145-2160.
Read now
Read now
Hyo-Soo Kim, Yangfeng Wu, Shing-Jong Lin, Chaicharn Deerochanawong, Robaayah Zambahari, Liancheng Zhao, Qiaoyi Zhang & Peter Yan. (2008) Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Current Medical Research and Opinion 24:7, pages 1951-1963.
Read now
Read now
Articles from other publishers (32)
Irene García-Fernández-Bravo, Ana Torres-Do-Rego, Antonio López-Farré, Francisco Galeano-Valle, Pablo Demelo-Rodriguez & Luis A. Alvarez-Sala-Walther. (2022) Undertreatment or Overtreatment With Statins: Where Are We?. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Konstantinos Tsioufis, José María Castellano Vázquez, Georgia Sykara, Franco Mondello Malvestiti & Joris van Vugt. (2021) Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy. Cardiology and Therapy 10:2, pages 445-464.
Crossref
Crossref
Lemlem G Gebremichael, Vijayaprakash Suppiah, Michael D Wiese, Lorraine Mackenzie, Craig Phillips, Desmond B Williams & Michael S Roberts. (2021) Efficacy and safety of statins in ethnic differences: a lesson for application in Indigenous Australian patient care. Pharmacogenomics 22:9, pages 553-571.
Crossref
Crossref
L. Zhang, S. Zhang, Y. Yu, H. Jiang & J. Ge. (2018) Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterolWirksamkeit und Sicherheit von Rosuvastatin vs. Atorvastatin zur Senkung des LDL-Cholesterins. Herz 45:6, pages 594-602.
Crossref
Crossref
Debabrata Roy, Tanmay Mahapatra, Kaushik Manna, Ayan Kar, Md Saiyed Rana, Abhishek Roy, Pallab Kumar Bose, Barnali Banerjee, Srutarshi Paul & Sandipta Chakraborty. (2020) Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. PLOS ONE 15:5, pages e0233230.
Crossref
Crossref
Yun Wang, Bryan P Yan, Brian Tomlinson & Vivian WY Lee. (2019) Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. European Journal of Preventive Cardiology 26:14, pages 1496-1506.
Crossref
Crossref
Qingzan Kong, Qing Zhu & Liqi Wang. (2018) Bayesian Meta-Analysis: The Effect of Statins on the Treatment of Hypercholesterolemia. International Journal of Pharmacology 14:2, pages 151-163.
Crossref
Crossref
Yundai Chen, Dandan Li, Jing Jing, Hongbing Yan, Jinghua Liu, Zhujun Shen, Stefan James & Christoph Varenhorst. (2017) Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study. Clinical Therapeutics 39:9, pages 1827-1839.e1.
Crossref
Crossref
Meor Fairuz Rizal Meor Anuar Shuhaili, Intan Nureslyna Samsudin, Johnson Stanslas, Shariful Hasan & Subashini C. Thambiah. (2017) Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. International Journal of Endocrinology and Metabolism In Press:In Press.
Crossref
Crossref
Juliana C. N. Chan, Alice P. S. Kong, Weihang Bao, Rana Fayyad & Rachel Laskey. (2016) Safety of atorvastatin in Asian patients within clinical trials. Cardiovascular Therapeutics 34:6, pages 431-440.
Crossref
Crossref
Sunghwan SuhChang Hee JungSoon-Jun HongJung-Sun KimByung Ju SongHyun Soon SohnSung Hee Choi. (2016) Economic Evaluation of Rosuvastatin and Atorvastatin for the Treatment of Dyslipidemia from a Korean Health System Perspective. Journal of Lipid and Atherosclerosis 5:1, pages 61.
Crossref
Crossref
Chetan P. Shah, Dayanand K. Kumbla, Asha Moorthy, S. Murthy, Pankaj Aneja, Jagdish Gotur, Anil Gupta, Raman Abhi, Rajeev Bansal, Subhash Sonawala, Anil G. Balani, R. Kedarnathan, Pankaj Soni & P. Chinnaiyan. (2015) A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). Journal of Indian College of Cardiology 5:4, pages 282-290.
Crossref
Crossref
Emily Peckham, Sally Brabyn, Liz Cook, Thomas Devlin, Jo Dumville & David J. Torgerson. (2015) The use of unequal randomisation in clinical trials — An update. Contemporary Clinical Trials 45, pages 113-122.
Crossref
Crossref
Bruce K. Birmingham, Sarah R. Bujac, Robert Elsby, Connie T. Azumaya, Cheryl Wei, Yusong Chen, Rogelio Mosqueda-Garcia & Helen J. Ambrose. (2015) Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?. European Journal of Clinical Pharmacology 71:3, pages 341-355.
Crossref
Crossref
Yi-Cong Ye, Xi-Liang Zhao & Shu-Yang Zhang. (2015) Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients. Chinese Medical Journal 128:2, pages 259-266.
Crossref
Crossref
Stephen P Adams, Sarpreet S Sekhon & James M Wright. (2014) Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
S. Kangwanvanich & S. Permpongkosol. (2014) Efficacy and safety of rosuvastatin in late-onset hypogonadism patients with dyslipidaemia. Andrologia 46:4, pages 430-436.
Crossref
Crossref
Miao Hu, Sandra S.H. Lui, Gary T.C. Ko & Brian Tomlinson. (2013) Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. International Journal of Cardiology 168:3, pages 3071-3073.
Crossref
Crossref
Yan‐Peng Li, Li‐rong Zhang, Min Jia & Xiang‐Jie Hu. (2013) Author's Response to Comments by Hu et al. The Journal of Clinical Pharmacology 52:11, pages 1770-1771.
Crossref
Crossref
Miao Hu, Valiant W.L. Mak & Brian Tomlinson. (2013)
Comments on
“CYP3AP1
*3 Allele Is Associated With Lipid‐Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women”
. The Journal of Clinical Pharmacology 52:11, pages 1768-1769.
Crossref
Crossref
Ping Wang. (2011) Statin dose in Asians: is pharmacogenetics relevant?. Pharmacogenomics 12:11, pages 1605-1615.
Crossref
Crossref
Claudio Aparício S Baptista. (2011) Rabdomiólise após exercício físico não intenso. Revista Brasileira de Medicina do Esporte 17:2, pages 142-146.
Crossref
Crossref
Juan Yang, Lu-jin Li, Kun Wang, Ying-chun He, Yu-cheng Sheng, Ling Xu, Xiao-hui Huang, Feng Guo & Qing-shan Zheng. (2010) Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients. Acta Pharmacologica Sinica 32:1, pages 116-125.
Crossref
Crossref
Junya Pattaraarchachai, Chalapati Rao, Warangkana Polprasert, Yawarat Porapakkham, Wansa Pao-in, Noppcha Singwerathum & Alan D Lopez. (2010) Cause-specific mortality patterns among hospital deaths in Thailand: validating routine death certification. Population Health Metrics 8:1.
Crossref
Crossref
B Tomlinson, M Hu, V W Y Lee, S S H Lui, T T W Chu, E W M Poon, G T C Ko, L Baum, L S Tam & E K Li. (2010) ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clinical Pharmacology & Therapeutics 87:5, pages 558-562.
Crossref
Crossref
Antonio M. GottoJrJr. (2009) Improving Lipid Goal Attainment. Circulation 120:1, pages 3-5.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Lipidology 20:1, pages 63-72.
Crossref
Crossref
Arthur TH Tan, Lip-Ping Low, Chin Hock Lim & Chee Eng Tan. (2009) Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 16:4, pages 509-516.
Crossref
Crossref
John Wlodarczyk, David Sullivan & Michael Smith. (2008) Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. The American Journal of Cardiology 102:12, pages 1654-1662.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:7.
Crossref
Crossref
Chern-En Chiang, Shao-Sung Huang & Shih-Hsien Sung. (2008) Efficacy and Safety of Rosuvastatin in Taiwanese Patients. Journal of the Chinese Medical Association 71:3, pages 113-118.
Crossref
Crossref
Gillian M. Keating & Dean M. Robinson. (2012) Rosuvastatin. American Journal of Cardiovascular Drugs 8:2, pages 127-146.
Crossref
Crossref